Whew, I can not imagine how convoluted the link between the accuracy of your poll and reality would be. Somehow I think it would travel across several worm holes and dimensions if it came out even close to the bleachers in the ball park.
I couldn't agree more. Chipster needs to be pressured to accomodate the instos that have invested and supported the company
I won't even bother listing all of milestones Gern has recently pasted. I won't even talk about the up coming milestones that are visible shortly down the road. All I've got to say is the share price a freaking joke and I'm
seriously miffed at Management. What a bunch of pikers.
smig, Yes in a perfect World you would be correct. But, I already have my positions established, and being overweight in GERN can not add any more, and, your belief that I should be praising their lack of IR is a bit of a strange conclusion. Ai brief lapse in IR in a stock that is momentum driven is an opportunity, a corporate culture of poor IR is a quagmire that spawns the adage: floats up like a feather and falls like a rock.
So, you have shareholders like myself that have large positions, that have been shareholders for many years, and are disappointed and disheartened in share price performance when looking at drug development.
I guess you are just one of the slow ones, and just another of the many that receives the ignore option. It really is amazing how Yahoo has always attracted the most challenged and most rude of the internet population.
Are you this rude in everyday life to people you interact with, or just act out on the net? And apparently independent of your rude behavior you are incredibly dense.
Gern's management certainly has either learned little or refuses to learn the value of not only leading a Company forward on a growth path, but also the skills involved in creating shareholder value as they move the company forward. I don't think they are even embarrassed by their ineptitude. The Instos that have large positions in GERN can't be happy with the share price performance and are probably the major holders of the 30 million short positions as hedges to protect them from lack of proactive investor relations and slow bio tech product to market timelines.
One more time I'm disappointed in management's ability to keep the IR ball in the air as they juggle the research balls.
Short Sale Restrictions
A short sale is the sale of a stock that a seller does not own or a sale which is consummated by the delivery of a stock borrowed by, or for the account of, the seller. Short sales are normally settled by the delivery of a security borrowed by or on behalf of the seller. The short seller later closes out the position by returning the borrowed security to the stock lender, typically by purchasing securities on the open market. Short sellers typically hope to profit from a downward price movement or seek to hedge the risk of a long position in the same or a related security.
In February 2010 the Commission adopted a new short sale price test restriction, which is commonly referred to as the “alternative uptick rule.” The alternative uptick rule is designed to restrict short selling from further driving down the price of a stock that has dropped more than 10 percent in one day compared to the closing price on the previous day.
It's a pleasure--the only one I'm experiencing this morning--to put your foul mouth on IGNORE. Frankly, I could care less what you have to say.
You need to get a grip. Continually posting on the Yahoo BB isn't going to do one thing either positive or negative with GERN's Share Price. How about taking a breath and refraining from posting as much. You think almost everyone here doesn't feel a strong sense of disappointment at today's knock down?
Maine, you have created 11 thousand posts on Yahoo. All of them saying the same thing. Think you have a bit of a problem. You know you can change your life, all you have to do is want to.
Maine is not a dope. He obviously is of above average intelligence. But, he appears to be clinically nuts. I've seen others on the net completely self destruct and although interesting to watch, it is always pitiful. I watched a guy back in the day, on Silicon Investor, in 3Cube, absolutely have a mental breakdown--that is something I'll never forget.
Then there was a guy on Audio Asylum that went off the deep end worrying about reversed phase in recordings.
The pump d jour will be price targets raised. The next MATERIAL pump will be next Monday when the Janssen deal is inked and the $35 million received.
Well, a little less than half the float is held by instos. I would expect to see more of the float go to the instos but, not sure how much or how fast. This is important stuff and can have huge benefits for the whole World, it will take some time, but you have to know they will be burning the midnight oil to explore various applications. I'm thinking we'll be very surprised how fast things move forward.
Yup, Gern can't be compared to Incyte. Gern has a drug that is pan cancer/combo possible with CRs. Incyte donesn't.. Early days for IMET, give it three years and see how the comparison works out.
Yeah, people can't seem to stay focused on what is in front of them. I really wonder what their expectations were prior to the CC, but I can only assume, judging by the comments-- that they seemed to have convinced themselves that something more Hollywood and less scientific was on the menu. Oh well, Yahoo, what else would one expect.
This is historic